Treace Medical Concepts, Inc.
NASDAQ:TMCIMedical - Devices
+$0.08 today
- Market cap
- $296.98M
- Beta
- 1.41
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.95
Volume 0.18M
Average 0.73M
TMCI Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Treace Medical Concepts, Inc.NASDAQ: TMCI
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation outflow shrinks to $0
Q1 FY2026 stock-based compensation was $0, compared with $8.69M a year earlier. Trailing-twelve-month stock-based compensation was $25.13M. Over 3 fiscal years it compounded at +61.0% a year.
Context
- Stock-based compensation amounted to 15.9% of revenue in FY2025, up 1.3 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $6.28M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 33.82M USD
- Year-over-year change
- +10.5%
- 4-year CAGR
- +77.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.82M | +10.5% |
| FY2024 | 2024-12-31 | 30.6M | +76.4% |
| FY2023 | 2023-12-31 | 17.35M | +113.9% |
| FY2022 | 2022-12-31 | 8.11M | +137.9% |
| FY2021 | 2021-12-31 | 3.41M | — |
Stock-Based Compensation vs competitors
How TMCI compares with its peers on the latest reported figures
- TMCI's LTM Mar 2026 stock-based compensation of $25.13M is the 3rd largest of the 8 companies compared; the peer median is $17.9M.
- Its year-over-year change of -21.2% is the 7th highest of 8, against a peer median of +19.7%.
- Stock-based compensation amounts to 12.1% of revenue for TMCI, versus a peer median of 7.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $32.42M | +19.7% | +40.5% | 25.4% | |
| LTM Mar 2026 | $27.48M | -5.7% | +25.8% | 31.9% | |
| LTM Mar 2026 | $25.13M | -21.2% | +61.0% | 12.1% | |
| LTM Mar 2026 | $19.89M | -13.9% | +24.1% | 6.6% | |
| LTM Mar 2026 | $17.9M | +22.5% | +38.6% | 7.4% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $13.6M | +94.2% | +15.5% | 14.3% |
| LTM Mar 2026 | $13.52M | +36.9% | -10.3% | 2.3% | |
| LTM Mar 2026 | $2.57M | -69.9% | -45.2% | 0.5% | |
| Peer median (excluding TMCI) | $17.9M | +19.7% | +24.1% | 7.4% | |
Competitors are the stored peer set for TMCI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (20.55M) | (42.82M) | (49.53M) | (55.74M) | (59M) |
| Depreciation & Amortization | 685K | 2.13M | 5.35M | 8.42M | 10.5M |
| Deferred Income Tax | 419K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.41M | 8.11M | 17.35M | 30.6M | 33.82M |
| Change in Working Capital | (1.33M) | (5.81M) | (9.74M) | (25.43M) | (8.58M) |
| Accounts Receivables | (4.23M) | (11.04M) | (9.3M) | (5.69M) | (2.09M) |
| Inventory | (3.09M) | (8.77M) | (9.85M) | (10.01M) | 3.22M |
| Accounts Payables | 1.79M | 4.61M | 3.17M | (1.31M) | (3.8M) |
| Other Working Capital | 4.19M | 9.39M | 6.24M | (8.42M) | (5.92M) |
| Other Non-Cash Items | 176K | 7.73M | 1.99M | 4.99M | 7.29M |
| Operating Cash Flow | (17.19M) | (30.65M) | (34.58M) | (37.17M) | (15.97M) |
| Capital Expenditures | (2.71M) | (14.84M) | (11.46M) | (11.59M) | (13.52M) |
| Acquisitions (Net) | 0 | 61.68M | (20M) | 0 | 0 |
| Purchases of Investments | 0 | (63.41M) | (169.87M) | (71.58M) | (40.57M) |
| Sales of Investments | 0 | 1.73M | 120.02M | 118.55M | 67.34M |
| Other Investing Activities | 0 | (61.68M) | 0 | 0 | 0 |
| Investing Cash Flow | (2.71M) | (76.52M) | (81.3M) | 35.38M | 13.25M |
| Debt Repayment | (1.79M) | 19.61M | 0 | 0 | 2.43M |
| Common Stock Issued | 109.44M | 2.19M | 109.4M | 428K | 546K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (989K) | (13K) | (268K) | (902K) |
| Financing Cash Flow | 107.65M | 20.81M | 109.38M | 160K | 2.08M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 87.75M | (86.36M) | (6.49M) | (1.63M) | (642K) |
| Free Cash Flow | (19.9M) | (45.49M) | (46.03M) | (48.76M) | (29.49M) |
Treace Medical Concepts, Inc.
NASDAQ:TMCI
Intrinsic Alpha fair value
Locked
Current Price
$4.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.